Takeda Pharmaceutical CEO on Business Strategy

The video discusses the company's financial performance, highlighting a successful 2022 with debt reduction and a focus on growth. It addresses the temporary slowdown in 2023 due to generic competition, with expectations for profit recovery starting in 2024. The company plans to increase shareholder returns through a progressive dividend policy. Significant investments in R&D have led to a robust product pipeline, including a dengue vaccine and an AI-discovered compound for autoimmune diseases. The company is undergoing a digital transformation, leveraging AI to enhance R&D and operations.

How did the company perform in 2022, and what was achieved regarding debt?

What is the company's outlook for growth after the slowdown in 2023?

What are the expectations for profit recovery after the fiscal year 2023?

What is the significance of the company's pipeline and its current status?

How does the company plan to address competition from generics?

What role does artificial intelligence play in the company's R&D transformation?

What are the expected timelines for the phase three program of Tag 279?